BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Taliglucerase alfa: Additional Phase III data

Top-line data from 26 evaluable patients in an open-label, crossover, international Phase III trial showed that mean hemoglobin and platelet counts, spleen volume and liver volume remained stable after patients switched from Cerezyme imiglucerase to an equivalent dose of IV taliglucerase alfa every 2 weeks for 9 months. One patient experienced a hypersensitivity reaction. The trial was originally designed to enroll 15 patients, but was expanded to include 30 patients as a result of the shortage of enzyme replacement therapy for Gaucher's patients. Genzyme Corp., a subsidiary...

Read the full 431 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >